These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 34544765)

  • 1. A Needs Assessment of Persons With Sickle Cell Disease in a Major Medical Center in North Carolina.
    Masese RV; Crego N; Douglas C; Rains G; Bonnabeau E; DeMartino T; Shah N; Tanabe P
    N C Med J; 2021; 82(5):312-320. PubMed ID: 34544765
    [No Abstract]   [Full Text] [Related]  

  • 2. Barriers and facilitators to care for individuals with sickle cell disease in central North Carolina: The emergency department providers' perspective.
    Masese RV; Bulgin D; Douglas C; Shah N; Tanabe P
    PLoS One; 2019; 14(5):e0216414. PubMed ID: 31063506
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of the InCharge Health Mobile App to Improve Adherence to Hydroxyurea in Patients With Sickle Cell Disease: User-Centered Design Approach.
    Alberts NM; Badawy SM; Hodges J; Estepp JH; Nwosu C; Khan H; Smeltzer MP; Homayouni R; Norell S; Klesges L; Porter JS; Hankins JS
    JMIR Mhealth Uhealth; 2020 May; 8(5):e14884. PubMed ID: 32383683
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identifying barriers to evidence-based care for sickle cell disease: results from the Sickle Cell Disease Implementation Consortium cross-sectional survey of healthcare providers in the USA.
    Smeltzer MP; Howell KE; Treadwell M; Preiss L; King AA; Glassberg JA; Tanabe P; Badawy SM; DiMartino L; Gibson R; Kanter J; Klesges LM; Hankins JS;
    BMJ Open; 2021 Nov; 11(11):e050880. PubMed ID: 34789492
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Integration of Mobile Health Into Sickle Cell Disease Care to Increase Hydroxyurea Utilization: Protocol for an Efficacy and Implementation Study.
    Hankins JS; Shah N; DiMartino L; Brambilla D; Fernandez ME; Gibson RW; Gordeuk VR; Lottenberg R; Kutlar A; Melvin C; Simon J; Wun T; Treadwell M; Calhoun C; Baumann A; Potter MB; Klesges L; Bosworth H;
    JMIR Res Protoc; 2020 Jul; 9(7):e16319. PubMed ID: 32442144
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interventions for chronic kidney disease in people with sickle cell disease.
    Roy NB; Fortin PM; Bull KR; Doree C; Trivella M; Hopewell S; Estcourt LJ
    Cochrane Database Syst Rev; 2017 Jul; 7(7):CD012380. PubMed ID: 28672087
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Understanding patient-related barriers to hydroxyurea use among adolescent and adult patients with sickle cell disease in Mulago and Kiruddu hospitals, Uganda, a qualitative study.
    Namaganda P; Nantume P; Mubiru KR; Twimukye A; Wiltshire CS
    BMC Health Serv Res; 2024 May; 24(1):666. PubMed ID: 38802815
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hydroxyurea (hydroxycarbamide) for sickle cell disease.
    Rankine-Mullings AE; Nevitt SJ
    Cochrane Database Syst Rev; 2022 Sep; 9(9):CD002202. PubMed ID: 36047926
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Level of utilization and provider-related barriers to the use of hydroxyurea in the treatment of sickle cell disease patients in Jos, North-Central Nigeria.
    Ofakunrin AO; Okpe ES; Afolaranmi TO; Olaosebikan RR; Kanhu PU; Adekola K; Dami N; Sagay AS
    Afr Health Sci; 2021 Jun; 21(2):765-774. PubMed ID: 34795734
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hydroxyurea therapy for sickle cell disease in community-based practices: a survey of Florida and North Carolina hematologists/oncologists.
    Zumberg MS; Reddy S; Boyette RL; Schwartz RJ; Konrad TR; Lottenberg R
    Am J Hematol; 2005 Jun; 79(2):107-13. PubMed ID: 15929107
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interventions for chronic kidney disease in people with sickle cell disease.
    Roy NB; Carpenter A; Dale-Harris I; Dorée C; Estcourt LJ
    Cochrane Database Syst Rev; 2023 Aug; 8(8):CD012380. PubMed ID: 37539955
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Surveillance for Sickle Cell Disease - Sickle Cell Data Collection Program, Two States, 2004-2018.
    Snyder AB; Lakshmanan S; Hulihan MM; Paulukonis ST; Zhou M; Horiuchi SS; Abe K; Pope SN; Schieve LA
    MMWR Surveill Summ; 2022 Oct; 71(9):1-18. PubMed ID: 36201430
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hydroxyurea (hydroxycarbamide) for sickle cell disease.
    Nevitt SJ; Jones AP; Howard J
    Cochrane Database Syst Rev; 2017 Apr; 4(4):CD002202. PubMed ID: 28426137
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Provider barriers to hydroxyurea use in adults with sickle cell disease: a survey of the Sickle Cell Disease Adult Provider Network.
    Lanzkron S; Haywood C; Hassell KL; Rand C
    J Natl Med Assoc; 2008 Aug; 100(8):968-73. PubMed ID: 18717150
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sickle-Cell Disease Co-Management, Health Care Utilization, and Hydroxyurea Use.
    Crego N; Douglas C; Bonnabeau E; Earls M; Eason K; Merwin E; Rains G; Tanabe P; Shah N
    J Am Board Fam Med; 2020; 33(1):91-105. PubMed ID: 31907250
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Perspectives of individuals with sickle cell disease on barriers to care.
    Phillips S; Chen Y; Masese R; Noisette L; Jordan K; Jacobs S; Hsu LL; Melvin CL; Treadwell M; Shah N; Tanabe P; Kanter J
    PLoS One; 2022; 17(3):e0265342. PubMed ID: 35320302
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Survey-Based Needs Assessment of Barriers to Optimal Sickle Cell Disease Care in the Emergency Department.
    Linton EA; Goodin DA; Hankins JS; Kanter J; Preiss L; Simon J; Souffront K; Tanabe P; Gibson R; Hsu LL; King A; Richardsona LD; Glassberg JA;
    Ann Emerg Med; 2020 Sep; 76(3S):S64-S72. PubMed ID: 32928465
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intentional and unintentional nonadherence to hydroxyurea among people with sickle cell disease: a qualitative study.
    Hodges JR; Phillips SM; Norell S; Nwosu C; Khan H; Luo L; Badawy SM; King A; Tanabe P; Treadwell M; Rojas Smith L; Calhoun C; Hankins JS; Porter J
    Blood Adv; 2020 Sep; 4(18):4463-4473. PubMed ID: 32941646
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hydroxyurea adherence and associated outcomes among Medicaid enrollees with sickle cell disease.
    Candrilli SD; O'Brien SH; Ware RE; Nahata MC; Seiber EE; Balkrishnan R
    Am J Hematol; 2011 Mar; 86(3):273-7. PubMed ID: 21328441
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pediatric residents' perceived barriers to opioid use in sickle cell disease pain management.
    Fearon A; Marsh A; Kim J; Treadwell M
    Pediatr Blood Cancer; 2019 Feb; 66(2):e27535. PubMed ID: 30387290
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.